Chengdu WestGene Biomedical Technology Co., Ltd. announced that it has received $21.45 million in funding from Qingdao Honline Huaxin Asset Management Co., Ltd.,Yingke Innovation Asset Management Co., Ltd.,Chengdu Guanghua Wutong Equity Investment Fund Management Co., Ltd. and Hangzhou Tigermed Consulting Co., Ltd.
December 05, 2022
Share
WestGene announced that it has raised $21,450,000 in a round of funding of its first tranche on December 6, 2022. The transaction included participation from Huaxin Asset Management,Yingke Innovation Asset Management Co., Ltd.,Chengdu Wenjiang Emerging Industry Fund,a fund managed by Chengdu Guanghua Wutong Equity Investment Fund Management Co., Ltd. and Hangzhou Tigermed Consulting Co., Ltd.
Beijing Konruns Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research and development, production and sales of drugs. The Company's main product Suling belongs to the haemocoagulase drug that activates the coagulation process, which is mainly used for hemostasis of superficial wound bleeding in surgical operations as well as the bleeding caused by postoperative, trauma and disease. The Companyâs present products under research include a range of innovative and generic drugs for tumors and blood. The Company mainly distributes its products in the domestic market.
Chengdu WestGene Biomedical Technology Co., Ltd. announced that it has received $21.45 million in funding from Qingdao Honline Huaxin Asset Management Co., Ltd.,Yingke Innovation Asset Management Co., Ltd.,Chengdu Guanghua Wutong Equity Investment Fund Management Co., Ltd. and Hangzhou Tigermed Consulting Co., Ltd.
BEIJING KONRUNS PHARMACEUTICAL CO.,LTD. 
